v3.26.1
Revenue (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2026202520262025
MACI implants, kits, and instruments
Implants based on contracted rate sold through a specialty pharmacy (a)
$49,892 $39,430 $91,694 $71,471 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
5,368 2,688 10,017 5,371 
Implants sold direct based on contracted rates (c)
7,493 8,903 14,902 17,325 
Implants sold direct subject to third-party reimbursement (d)
1,928 991 3,989 2,615 
Biopsy kits and instruments - direct bill614 642 1,220 1,238 
Change in estimates related to prior periods (e)
211 804 82 1,735 
Total MACI implants, kits, and instruments65,506 53,458 121,904 99,755 
Epicel
Direct bill (hospital)10,404 8,614 21,289 13,578 
NexoBrid1,547 1,168 2,689 2,505 
Total revenue$77,457 $63,240 $145,882 $115,838 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer and is subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.